TY - JOUR
T1 - Vlp-based vaccines as a suitable technology to target trypanosomatid diseases
AU - Queiroz, Aline Maria Vasconcelos
AU - Oliveira, Johny Wysllas de Freitas
AU - Moreno, Cláudia Jassica
AU - Guérin, Diego M.A.
AU - Silva, Marcelo Sousa
N1 - Funding Information:
This research was funded by Global Health and Tropical Medicine (Grant number IHMT UID/multi/04413/2013 and Grant number PTDC/CVT-CVT/28908/2017), Funda??o para Ci?ncia e Tecnologia (FCT), Portugal; Grant GIU18/172 Grupos de Investigaci?n de la UPV/EHU, and Grant from CSIC Programa I-COOP+2020 (ICOOPB20503), Spain.A.M.V.Q., J.W.d.F.O., and C.J.M. thanks to the financial support (PhD scholar-ships) provided by CNPq and CAPES, Brazil. M.S.S. thanks to CNPq for the Research Grant (Bolsa de Produtividade em Pesquisa). We are also grateful to Paulo Fanado and Laysa Ohanna for editing this manuscript.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei. In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite–host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids.
AB - Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei. In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite–host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids.
KW - African try-panosomiasis
KW - Chagas disease
KW - Leishmaniasis
KW - Trypanosomatids
KW - Vaccine
KW - Virus-like particles
UR - http://www.scopus.com/inward/record.url?scp=85102682984&partnerID=8YFLogxK
U2 - 10.3390/vaccines9030220
DO - 10.3390/vaccines9030220
M3 - Review article
AN - SCOPUS:85102682984
VL - 9
SP - 1
EP - 9
JO - Vaccines
JF - Vaccines
IS - 3
M1 - 220
ER -
